Conference Coverage
Latest News
Oct 05, 2026 | Opinion
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
Oct 05, 2026
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
Oct 05, 2026
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
Oct 02, 2026
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
Oct 02, 2026
Advertisement
Shorts
1:29
Why female sexual health is often overlooked in bladder cancer care
2 hours ago
by
Armine K. Smith, MD
1:07
How APPs can expand access to clinical trials
5 days ago
by
Mary Dunn, MSN, RN, NP-C, OCN
0:28
What policymakers must do to preserve patient choice
6 days ago
by
Celeste Kirschner, CAE, MHSA
1:14
Why the bladder diary matters in nocturia workup
7 days ago
by
Kari A.O. Tikkinen, MD, PhD
0:50
3 actionable steps to improve PSMA-PET access
10 days ago
by
Juan Gómez Rivas, MD, FEBU, PhD
0:23
Site-neutral payment and the future of community urology
11 days ago
by
Celeste Kirschner, CAE, MHSA
0:51
Reassessing goals of care throughout cancer treatment
12 days ago
by
Mary Dunn, MSN, RN, NP-C, OCN
1:17
Neoadjuvant therapy before prostatectomy: Assessing functional outcomes
13 days ago
by
Adam B. Weiner, MD(+1 more)
0:40
How unequal PSMA-PET access may affect prostate cancer care
14 days ago
by
Juan Gómez Rivas, MD, FEBU, PhD
0:33
What a positive NeoBLAST trial would mean for MIBC care
17 days ago
by
Marie-Pier St-Laurent, MD, FRCSC
From GSM guidance to HRT reform: A landmark year for women’s health
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
Inguinal lymph node dissection in penile cancer
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
Inside HoLEP: Irina Jaeger, MD, discusses patient selection and technique
Jaeger emphasizes that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication.
Videos
Urology Times Digital Edition
"Deep ILND is indicated for clinically positive lymph nodes and/or positive lymph nodes on frozen pathological analysis of the superficial nodal packet," write Bahrom J. Ostad, MD, and Stephen H. Culp, MD, PhD, FACS.
"The overall 0% impact to urology does not help urology practices deal with increasing costs incurred for staff, rent, supplies, and other overhead," write Jonathan Rubenstein, MD, and Mark Painter.
"If 2025 showed us anything, it is the power of combining scientific progress with public engagement," writes Michael S. Cookson, MD, MMHC, FACS.
"Once money is in a Roth IRA, the withdrawal rules depend on whether the funds are contributions, conversions, or earnings," writes Julie Khazan, CFP.
The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial.
The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.
"The OBBA includes broad and sweeping changes that will have a profound impact," writes Allan Shen, CFP.
The ENDURE 1 study plans to enroll up to 60 patients with benign ureteric strictures.
The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.
Jaeger emphasized that the ideal HoLEP candidate is any patient with bothersome lower urinary tract symptoms due to BPH, including those with urinary retention or intolerance to medication
Continuing Medical Education
Advertisement
All News
Advertisement
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
Armine K. Smith, MD, discusses the importance of integrating sexual health into bladder cancer care, including proactive counseling, preservation strategies, and multidisciplinary support.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Advertisement
Using PSMA-PET imaging and genomic testing to obtain better information earlier in the disease course changes what clinicians can do with diagnosis and treatment planning.
The registrational study is designed to evaluate the diagnostic performance of 68Ga-DOTA-RM2 vs histopathology in prostate cancer.
One year following the approval of the gemcitabine intravesical system, Joseph Jacob, MD, reflects on the expanding treatment landscape in BCG-unresponsive NMIBC.
A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
The PDUFA target action date is in the fourth quarter of 2026.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
3
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
4
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
5